Pharmacophore-based virtual screening and density functional theory approach to identifying novel butyrylcholinesterase inhibitors

Aim:To identify the critical chemical features, with reliable geometric constraints, that contributes to the inhibition of butyrylcholinesterase (BChE) function.Methods:Ligand-based pharmacophore modeling was used to identify the critical chemical features of BChE inhibitors. The generated pharmacophore model was validated using various techniques, such as Fischer's randomization method, test set, and decoy set. The best pharmacophore model was used as a query in virtual screening to identify novel scaffolds that inhibit BChE. Compounds selected by the best hypothesis in the virtual screening were tested for drug-like properties, and molecular docking study was applied to determine the optimal orientation of the hit compounds in the BChE active site. To find the reactivity of the hit compounds, frontier orbital analysis was carried out using density functional theory.Results:Based on its correlation coefficient (0.96), root mean square (RMS) deviation (1.01), and total cost (105.72), the quantitative hypothesis Hypo1 consisting of 2 HBA, 1 Hy-Ali, and 1 Hy-Ar was selected as the best hypothesis. Thus, Hypo1 was used as a 3D query in virtual screening of the Maybridge and Chembridge databases. The hit compounds were filtered using ADMET, Lipinski's Rule of Five, and molecular docking to reduce the number of false positive results. Finally, 33 compounds were selected based on their critical interactions with the significant amino acids in BChE's active site. To confirm the inhibitors' potencies, the orbital energies, such as HOMO and LUMO, of the hit compounds and 7 training set compounds were calculated. Among the 33 hit compounds, 10 compounds with the highest HOMO values were selected, and this set was further culled to 5 compounds based on their energy gaps important for stability and energy transfer. From the overall results, 5 hit compounds were confirmed to be potential BChE inhibitors that satisfied all the pharmacophoric features in Hypo1.Conclusion:This study pinpoints important chemical features with geometric constraints that contribute to the inhibition of BChE activity. Five compounds are selected as the best hit BchE-inhibitory compounds.

[1]  O. Lockridge,et al.  Complete amino acid sequence of human serum cholinesterase. , 1987, The Journal of biological chemistry.

[2]  M. Froment,et al.  Kinetic analysis of butyrylcholinesterase-catalyzed hydrolysis of acetanilides. , 2007, Biochimica et biophysica acta.

[3]  Om Silakari,et al.  Three dimensional pharmacophore modelling for c-Kit receptor tyrosine kinase inhibitors. , 2010, European journal of medicinal chemistry.

[4]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[5]  C. Geula,et al.  Neurobiology of butyrylcholinesterase , 2003, Nature Reviews Neuroscience.

[6]  M. Wierdl,et al.  Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. , 2007, Journal of medicinal chemistry.

[7]  N. Greig,et al.  Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine. , 2006, Journal of Medicinal Chemistry.

[8]  N. Harrison An Introduction to Density Functional Theory , 2002 .

[9]  Wei Li,et al.  Investigation of binding features: Effects on the interaction between CYP2A6 and inhibitors , 2010, J. Comput. Chem..

[10]  Zhihai Liu,et al.  Evaluation of the performance of four molecular docking programs on a diverse set of protein‐ligand complexes , 2010, J. Comput. Chem..

[11]  R. Borges,et al.  A theoretical antioxidant pharmacophore for resveratrol. , 2009, European journal of medicinal chemistry.

[12]  O. Lockridge,et al.  Association of tetramers of human butyrylcholinesterase is mediated by conserved aromatic residues of the carboxy terminus. , 1999, Chemico-biological interactions.

[13]  M. Mesulam,et al.  Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine , 2002, Neuroscience.

[14]  C. Geula,et al.  Butyrylcholinesterase activity in the rat forebrain and upper brainstem: Postnatal development and adult distribution , 2007, Experimental Neurology.

[15]  D. Selkoe Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[16]  D. Quinn,et al.  Acetylcholinesterase: enzyme structure, reaction dynamics, and virtual transition states , 1987 .

[17]  E. Duysen,et al.  Sensitivity of butyrylcholinesterase knockout mice to (--)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission. , 2007, Toxicology.

[18]  C. Pérez,et al.  Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties. , 2006, Journal of medicinal chemistry.

[19]  A. Cavalli,et al.  Acetylcholinesterase inhibitors for potential use in Alzheimer's disease: molecular modeling, synthesis and kinetic evaluation of 11H-indeno-[1,2-b]-quinolin-10-ylamine derivatives. , 2000, Bioorganic & medicinal chemistry.

[20]  M. Karplus,et al.  CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .

[21]  S. Brimijoin,et al.  Abundant Tissue Butyrylcholinesterase and Its Possible Function in the Acetylcholinesterase Knockout Mouse , 2000, Journal of neurochemistry.

[22]  R. Margalit,et al.  Butyrylcholinesterase formulated in liposomes , 1999, Biotechnology and applied biochemistry.

[23]  M. Mesulam,et al.  Butyrylcholinesterase in the life cycle of amyloid plaques , 1997, Annals of neurology.

[24]  H. Mehrani Protective effect of polyurethane immobilized human butyrylcholinesterase against parathion inhalation in rat. , 2004, Environmental toxicology and pharmacology.

[25]  A. Çokuğraş,et al.  Butyrylcholinesterase : Structure and Physiological Importance , 2003 .

[26]  D. O'Connor,et al.  The cholinesterases: analysis by pharmacogenomics in man. , 2008, Chemico-biological interactions.

[27]  N. Cutler,et al.  Centrally acting antiemetics mitigate nausea and vomiting in patients with Alzheimer's disease who receive rivastigmine. , 2002, Clinical neuropharmacology.

[28]  E. Begg,et al.  Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice , 2006, Pharmacological Reviews.

[29]  C. Venkatachalam,et al.  LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites. , 2003, Journal of molecular graphics & modelling.

[30]  J. Sussman,et al.  Structure and functions of acetylcholinesterase and butyrylcholinesterase. , 1993, Progress in brain research.

[31]  Sugunadevi Sakkiah,et al.  3D QSAR pharmacophore based virtual screening and molecular docking for identification of potential HSP90 inhibitors. , 2010, European journal of medicinal chemistry.

[32]  M. Vitorović-Todorović,et al.  4-Aryl-4-oxo-N-phenyl-2-aminylbutyramides as acetyl- and butyrylcholinesterase inhibitors. Preparation, anticholinesterase activity, docking study, and 3D structure-activity relationship based on molecular interaction fields. , 2010, Bioorganic & medicinal chemistry.

[33]  F. Vallette,et al.  Molecular and cellular biology of cholinesterases , 1993, Progress in Neurobiology.

[34]  O. Lockridge,et al.  Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase. , 2008, Journal of medicinal chemistry.

[35]  Yvain Nicolet,et al.  Crystal Structure of Human Butyrylcholinesterase and of Its Complexes with Substrate and Products* , 2003, Journal of Biological Chemistry.

[36]  S. Sakkiah,et al.  Identification of critical chemical features for Aurora kinase-B inhibitors using Hip-Hop, virtual screening and molecular docking , 2011 .

[37]  S. Brimijoin,et al.  Predicted Michaelis-Menten Complexes of Cocaine-Butyrylcholinesterase , 2001, The Journal of Biological Chemistry.

[38]  Asim Kumar Debnath,et al.  Pharmacophore mapping of a series of 2,4-diamino-5-deazapteridine inhibitors of Mycobacterium avium complex dihydrofolate reductase. , 2002, Journal of medicinal chemistry.

[39]  Tetsuo Satoh,et al.  Structure, function and regulation of carboxylesterases. , 2006, Chemico-biological interactions.

[40]  R. K. Guy,et al.  Planarity and constraint of the carbonyl groups in 1,2-diones are determinants for selective inhibition of human carboxylesterase 1. , 2007, Journal of medicinal chemistry.

[41]  Simone Brogi,et al.  Pharmacophore Modeling for Qualitative Prediction of Antiestrogenic Activity , 2009, J. Chem. Inf. Model..

[42]  A. Main Mode of action of anticholinesterases , 1979 .

[43]  B. P. Doctor,et al.  Bioscavengers for the protection of humans against organophosphate toxicity. , 2005, Chemico-biological interactions.

[44]  A. Burgen The mechanism of action of anticholinesterase drugs. , 1949, British journal of pharmacology and chemotherapy.

[45]  E. Duysen,et al.  Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. , 2005, Biochemical pharmacology.

[46]  L. Bartolotti,et al.  An Introduction to Density Functional Theory , 2007 .

[47]  A. Robitzki,et al.  The key role of butyrylcholinesterase during neurogenesis and neural disorders: an antisense-5′butyrylcholinesterase-DNA study , 2000, Progress in Neurobiology.

[48]  E. Giacobini Cholinesterases: New Roles in Brain Function and in Alzheimer's Disease , 2003, Neurochemical Research.

[49]  Asim Kumar Debnath,et al.  Generation of predictive pharmacophore models for CCR5 antagonists: study with piperidine- and piperazine-based compounds as a new class of HIV-1 entry inhibitors. , 2003, Journal of medicinal chemistry.

[50]  E. Perry,et al.  CHANGES IN BRAIN CHOLINESTERASES IN SENILE DEMENTIA OF ALZHEIMER TYPE , 1978, Neuropathology and applied neurobiology.